FOLH1 and posterior cortical atrophy: A recent study of Sathekge M et al. assessed the therapeutic outcome of 225Ac-PSMA-617 in seventeen advanced PCa patients of which the results showed a good anti-tumoral effect assessed by serum PSA level and 68Ga-PSMA-PET/CT as seen in 94.1% of patients.